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hepatic fibrosis despite its risk and invasiveness. The aspartate aminotransferase/platelet ra-
tio index (APRI) could noninvasively predict the severity of hepatic fibrosis in chronic hepatitis
C (CHC) patients. Whether fibrosis index based on four factors (FIB-4) could better predict the
severity of hepatic fibrosis than APRI in CHC patients remains inconclusive.
Methods: This retrospective study enrolled 1473 CHC patients (784 men and 689 women)
with liver biopsy and clinical data including age, aspartate aminotransferase, alanine
aminotransferase, and platelet count. FIB-4 and APRI were calculated with a formula using
the four clinical parameters. Hepatic fibrosis was staged using the Metavir classification
system.
Results: The areas under the receiver operating characteristics of FIB-4 for the diagnosis
of significant fibrosis ( F2), advanced fibrosis ( F3), and cirrhosis (F4) were 0.816
[95% confidence interval (CI), 0.795e0.836], 0.827 (95% CI, 0.806e0.849), and 0.849
(95% CI, 0.830e0.867), respectively, compared with those of APRId0.799 (95% CI, 0.778
e0.819), 0.791 (95% CI, 0.770e0.812), and 0.802 (95% CI, 0.781e0.922). In addition, theave no conflicts of interest relevant to this article.
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924 C.-C. Wang et al.areas under the receiver operating characteristics of FIB-4 were significantly greater
than those of APRI for patients with advanced fibrosis and cirrhosis, respectively
(p < 0.0001).
Conclusion: FIB-4 could predict hepatic fibrosis in CHC patients. By adding two parameters
(age and alanine aminotransferase), FIB-4 better predicts advanced fibrosis and cirrhosis
than APRI in CHC patients.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic hepatic C virus (HCV) infection is one of the
common chronic liver diseases worldwide, leading to the
complications such as cirrhosis, liver decompensation, and
hepatocellular carcinoma.1,2 Chronic HCV infection can
induce hepatic fibrogenesis, and the severity of hepatic
fibrosis is closely associated with long-term prognosis in
chronic hepatitis C (CHC) patients.3 In addition, advanced
fibrosis is one of the factors associated with unfavorable
response to standard of care using interferon and riba-
virin.4,5 Thus, it is important to determine the severity of
hepatic fibrosis in our clinical practice. However, the
severity of hepatic fibrosis could not be easily measured
by imaging modalities such as ultrasound or computed
tomography. Although liver biopsy with subsequent his-
tological examination is currently the gold standard to
stage hepatic fibrosis, it is invasive and carries the risk of
complications such as pain or bleeding.6 In addition, small
sampling area and interobserver variability could
decrease its accuracy.7
Transient elastography, which was recently introduced
to measure liver stiffness, can predict the severity of
hepatic fibrosis even in dialysis CHC patients.8,9 Although
transient elastography is noninvasive, the instrument is
expensive and thus not widely available. The scores of
aspartate aminotransferase/platelet ratio index (APRI)
and fibrosis index based on four factors (FIB-4) are easily
obtained through a formula using four clinical parame-
tersdaspartate aminotransferase (AST), platelet count,
age, and alanine aminotransferase (ALT) levels. APRI has
been confirmed to precisely predict the severity of he-
patic fibrosis in patients or even hemodialysis patients
with CHC.10,11 The FIB-4 score is derived by adding two
parameters (age and ALT in the backbone of APRI), and it
was first developed to predict hepatic fibrosis in a
cohort of patients with HCV and human immunodeficency
virus (HIV) coinfection.12 Later on, its predictive value was
further validated in HCV monoinfected patients.13 A pre-
vious study showed that FIB-4 was useful in predicting
significant fibrosis after liver transplant, independent
of etiology.14 Another report suggested that FIB-4
could predict liver-related death in a cohort of CHC pa-
tients with or without HIV infection.15 Nevertheless,
whether FIB-4 is better than APRI in predicting the
severity of hepatic fibrosis or cirrhosis in CHC patients
remains unclear. Thus, we conducted a large-scale retro-
spective study to solve the clinically important and rele-
vant issues.Methods
Study overview
Between 2006 and 2013, a total of 1473 CHC adult patients
who received percutaneous liver biopsy prior to antiviral
treatment in Taipei Tzu Chi Hospital and National Taiwan
University Hospital in Taipei, Taiwan were retrospectively
recruited in the study. All patients had positive anti-HCV
antibody and detectable HCV RNA for at least 6 months.
They had no other known causes of hepatitis such as alco-
holism or use of hepatotoxic drug, and were negative for
hepatitis B virus or HIV coinfection. The exclusion criteria
were as follows: (1) patients had hepatocellular carcinoma;
(2) patients received liver transplantation; and (3) patients
received platelet transfusion recently. Demographic,
biochemical, and virological data including age, sex, AST,
ALT, HCV RNA, genotype, and platelet count were obtained
from each patient at the time of liver biopsy. The formula
used for APRI is:
AST level (/upper limit of normal)/platelet count
[109/L]  100, (1)
and the formula used for FIB-4 is:
age (years)  AST/[platelet count (109/L)  ALT1/2]. (2)Biochemical and virological tests
The biochemical data were measured with an autoanalyzer
(ROCHE ANALYTICS; Roche Professional Diagnostics, Penz-
berg, Germany). The upper limit of normal ALT level is
34 U/L for females and 45 IU/L for males. The upper limit of
normal AST is 40 IU/L for both males and females. The HCV
RNA level and genotype were determined as previously
described.16
Histological evaluations of liver biopsy specimens
Echo-guided percutaneous liver biopsy was performed from
the right hepatic lobe using a 16-gauge biopsy needle
(Temno Evolution, Allegiance, McGaw Park, IL, USA).17,18
The sampling tissues were fixed with formalin, embedded
with paraffin, and stained with hematoxylin and eosin. All
biopsy samples were evaluated by experienced pathologists
who were blinded to the clinical data of the patients. The
Table 1 Baseline patient characteristics.
Characteristics Patients (N Z 1473)
Age (y) 54.4 (11.5)
Male, n (%) 784 (53.2)
AST (IU/L) 92 (75)
ALT (IU/L) 134 (106)
Platelet count (109/L) 172 (59)
APRI 1.91 (2.09)
FIB-4 3.15 (2.82)
Fibrosis stage (Metavir), n (%)
0 27 (1.8)
1 352 (23.9)
2 541 (36.7)
3 186 (12.6)
4 367 (24.9)
HCV genotype, n (%)a
1 804 (58.9)
2 465 (34.1)
Mixed 1 and 2 2 (0.1)
3 76 (5.6)
6 14 (1.0)
Unclassified 3 (0.2)
HCV RNA level (IU/mL)a 3,155,404 (6,092,998)
Data are presented as mean (SD) unless otherwise indicated.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; APRI Z AST/platelet count ratio index; FIB-
4 Z fibrosis index based on four factors; HCV Z hepatitis C
virus; SD Z standard deviation.
a HCV genotype and HCV RNA level were available in 1364
patients.
FIB-4 better than APRI in chronic hepatitis C 925severity of hepatic fibrosis was staged using the Metavir
fibrosis score, ranging from F0 to F4. Significant fibrosis,
advanced fibrosis, and cirrhosis were defined as fibrosis
stage  F2,  F3, and F4, respectively. Most patients fol-
lowed at the National Taiwan University Hospital had > 1
liver biopsies. However, only biopsy results obtained prior
to interferon plus ribarivin therapy were included for
analysis in this study.Ethical considerations
The study was performed in accordance with the princi-
ples of the 1975 Declaration of Helsinki and approved
by the Ethical Committee of Taipei Tzu Chi Hospital,
Buddhist Tzu Chi Medical Foundation, which waived
the requirement for study design-specific informed
consent.Table 2 Distribution of hepatic fibrosis stage according to the
F0 F1
Patients, n (%) 27 (1.8) 352 (23.9)
APRI 0.82  0.72 0.93  0.80
FIB-4 1.47  0.61 1.56  0.91
Data are presented as mean (SD) unless otherwise indicated.
APRI Z aspartate aminotransferase to platelet ratio index; SD Z staStatistical analysis
Continuous variables including age, AST, ALT, platelet
count, APRI, FIB-4, and HCV RNA were expressed as mean
(standard deviation). Categorical variables were expressed
by patient number and percentages. The diagnostic accu-
racy of APRI and FIB-4 were evaluated using receiver
operating characteristics (ROC) curves, and the areas under
the ROC curves (AUROCs) for APRI and FIB-4 were expressed
as mean [95% confidence interval (CI)] and compared by c
statistics.19 Furthermore, the sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value
(NPV), positive likelihood ratio (LRþ), and negative likeli-
hood ratio (LR) of FIB-4 were further evaluated by
choosing the selected cutoff values. Statistical analyses
were performed using SAS 9.1 (SAS Institute Inc., Cary, NC,
USA). All tests were two-tailed, and p < 0.05 was consid-
ered statistically significant.Results
Patients
Overall, 784 men and 689 women were enrolled in the
study. Their mean age was 54.4  11.5 years. The mean
serum AST and ALT levels were 92 IU/L and 134 IU/L,
respectively. The mean platelet count was 172  109/L.
With regard to hepatic fibrosis, 27 (1.8%), 352 (23.9%), 541
(36.7%), 186 (12.6%), and 367 (24.9%) of these patients
were staged as F0, F1, F2, F3, and F4, respectively. Among
these patients, 1364 (92.6%) had available data for HCV
RNA level and genotype. The mean viral load was
3.16  106 IU/mL. Most patients (93.2%) had HCV genotype
1 and/or 2 infection (Table 1). The APRI and FIB-4 scores of
patients with different stages of hepatic fibrosis are shown
in Table 2.
Comparison of diagnostic accuracy between APRI
and FIB-4
The AUROCs of FIB-4 were significantly greater than
those of APRI in patients with advanced fibrosis [0.827
(95% CI, 0.806e0.849) vs. 0.791 (95% CI, 0.770e0.812),
p < 0.0001] and cirrhosis [0.849 (95% CI, 0.830e0.867) vs.
0.802 (95% CI, 0.781e0.867), p < 0.0001] (Figure 1).
However, the AUROC of FIB-4 tended to be greater than
that of APRI in patients with significant fibrosis [0.816
(95% CI, 0.795e0.836) vs. 0.799 (95% CI, 0.778e0.819),
p Z 0.06].Metavir classification.
F2 F3 F4
541 (36.7) 186 (12.6) 367 (24.9)
1.65  2.32 2.24  1.89 3.14  2.12
2.63  2.74 3.46  2.16 5.42  3.09
ndard deviation.
Figure 1 Comparison of the area under the receiver operating characteristic curves (AUROC) of FIB-4 and APRI for patients with
significant fibrosis (Metavir fibrosis  F2), advanced fibrosis ( F3) and cirrhosis (F4). APRIZ aspartate aminotransferase/platelet
ratio index; FIB-4 Z fibrosis index based on four factors.
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and FIB-4 categorized by HCV genotype 1 or 2
In 804 patients with chronic genotype 1 HCV infection, the
AUROCs of FIB-4 were significantly greater than those of
APRI in patients with advanced fibrosis [0.834 (95% CI,
0.807e0.859) vs. 0.807 (95% CI, 0.778e0.834), p Z 0.0087]
and cirrhosis [0.858 (95% CI, 0.832e0.881) vs. 0.817 (95% CI,
0.789e0.843), p Z 0.0001]. However, the AUROC of FIB-4
was not different with that of APRI in patients with signif-
icant fibrosis [0.813 (95% CI, 0.784e0.839) vs. 0.799 (95% CI,
0.769e0.826), p Z 0.28]. In 465 patients with chronic ge-
notype 2 HCV infection, the AUROCs of FIB-4 were signifi-
cantly greater than those of APRI in patients with advanced
fibrosis [0.806 (95% CI, 0.767e0.841) vs. 0.770 (95% CI,
0.729e0.807), p Z 0.0193] and cirrhosis [0.818 (95% CI,
0.78e0.852) vs. 0.767 (95% CI, 0.726e0.804), p Z 0.0029].
However, the AUROC of FIB-4 was not significantly different
from that of APRI in patients with significant fibrosis [0.817(95% CI, 0.779e0.851) vs. 0.803 (95% CI, 0.764e0.838),
p Z 0.32].
Selective cutoff values of FIB-4 for different stages
of hepatic fibrosis
If FIB-4 was <1.45, the NPV was 92.7% and the sensitivity
was 95.1% for advanced fibrosis (Table 3). If FIB-4 > 3.25,
the PPV was 71.4% and the specificity was 84.9% for
advanced fibrosis.Discussion
In this study, 1473 CHC patients with mainly genotype 1 and/
or 2 infection were enrolled. By using AUROC analysis, our
data show that both FIB-4 andAPRI can predict the severity of
hepatic fibrosis in CHC patients. In addition, FIB-4 can better
predict advancedfibrosis andcirrhosis thanAPRI (p< 0.0001).
Table 3 Selective cutoff values of FIB-4 for different
stages of hepatic fibrosis.
 F2  F3 F4
Prevalence (%) 74.2 37.5 24.9
Cutoff value 0.75 2.15 1.45 3.25 2.00 6.50
PPV 77.6 91.0 47.6 71.4 38.9 78.4
NPV 82.7 46.3 92.7 79.1 95.3 80.7
Sensitivity 98.7 67.6 95.1 62.8 92.4 29.7
Specificity 17.7 80.7 37.1 84.9 51.9 97.3
LRþ 1.20 3.51 1.51 4.15 1.02 10.96
LR 0.07 0.40 0.13 0.44 0.15 0.72
FIB-4 Z fibrosis index based on four factors; LRþ Z positive
likelihood ratio; LR Z negative likelihood ratio;
NPV Z negative predictive value; PPV Z positive predictive
value.
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tients. In clinical practice, if FIB-4 was < 1.45, the NPV for
advanced hepatic fibrosis was 92.7%. If the FIB-4 index was>
2.15, the PPV of significant fibrosis ( F2) was 91%.
Hepatic fibrosis is one of the important factors associ-
ated with the long-term prognosis of CHC patients. If
noninvasive methods could accurately predict the severity
of hepatic fibrosis, the majority of liver biopsies could be
avoided.20 In recent years, transient elastography has been
accepted as an alternative method to assess the severity of
hepatic fibrosis. However, several limitations could affect
its clinical usefulness. The cost of transient elastography
may preclude its widespread availability, and it has a
decreased accuracy in specific population groups including
obese patients or patients with ascites or hepatitis
flare.21e23 APRI and FIB-4 can predict the severity of he-
patic fibrosis in CHC patients. Furthermore, the difference
of FIB-4 per year was reported to predict the risk of disease
progression to cirrhosis.24,25 In addition, they are easily
calculated in clinical practice, and serial data can be ob-
tained to follow up on disease progression.
Our results provided additional evidence that FIB-4 can
predict the severity of hepatic fibrosis, not only in pre-
dicting advanced fibrosis or cirrhosis but also in significant
fibrosis (AUROC Z 0.816; 95% CI, 0.795e0.836). A previous
French study validated that FIB-4 could predict advanced
fibrosis or cirrhosis in HCV-monoinfected patients with 847
liver biopsies and 780 FIB-4 index values. Although their
AUROC seems better than ours in predicting advanced
fibrosis or cirrhosis (0.91 and 0.85 vs. 0.85 and 0.83,
respectively), the data of viral load and genotype were not
provided. In this study, the sample size was larger and all
patients were Taiwanese with mainly (92.6%) HCV genotype
1 and/or 2 infection.
To the best of our knowledge, this study is the first one
from Asia to validate the superiority of FIB-4 compared with
APRI in CHC patients. APRI is known to be associated with
the severity of hepatic fibrosis in CHC patients.26 By adding
two clinical parameters (age and ALT) to the backbone of
APRI, FIB-4 better predicted advanced fibrosis and cirrhosis
than APRI in CHC patients. A recent study from Egypt found
that FIB-4 had the best performance curve in predicting
moderate or severe fibrosis ( F2) compared with APRIusing AUROC analysis.27 However, PPV and NPV (0.56 and
0.76, respectively) seemed lower than those in previous
reports. In addition, the statistical significance was not
confirmed. Recently, a large cohort of Western CHC pa-
tients showed that the AUROC of FIB-4 was significantly
higher than that of APRI in predicting advanced fibrosis.28
Moreover, another two studies found that FIB-4 was supe-
rior to APRI in the prediction of severe fibrosis and
cirrhosis.29,30 In clinical practice, because these high-risk
patients could be identified using FIB-4 score, they could
receive frequent monitoring, and aggressive treatment
should be given as early as possible.
Taking these data together, we suggest using FIB-4
instead of APRI to predict hepatic fibrosis in clinical prac-
tice, and urge practicing physicians to measure platelet
count in addition to routine AST, ALT, and AFP testing as
well as ultrasound examination for the regular follow-up of
CHC patients. Just like the role of estimated glomerular
filtration rate (eGFR) (formula Z 186.3  serum creatinine
1.154  age 0.203  (0.742 if female)  (1.212 if black))
in the prediction of renal function,31 if FIB-4 index can be
automatically calculated with the aid of a computer, we
can easily understand the status of hepatic fibrosis and its
progression.
This study has several unique features. First, this is the
first validation of FIB-4 in Asian CHC patients. Thus, we can
validate the power of FIB-4 for predicting hepatic fibrosis in
Asian patients. Second, the sample size is large, and
different severity levels of hepatic fibrosisdincluding sig-
nificant, advanced fibrosis, or cirrhosisdwere analyzed
using AUROC between APRI and FIB-4. Thus, we could un-
derstand the performance of FIB-4 in different severity
levels of hepatic fibrosis compared with APRI. Third, diag-
nostic accuracy between FIB-4 and APRI was compared not
only in the overall population but also in subgroups cate-
gorized by HCV genotype 1 or 2. However, several limita-
tions are also noted. First, although a small proportion of
patients (7.4%) lacked data on HCV RNA and genotype, the
percentage was acceptable. Second, the possible interob-
server variability between different pathologists in deter-
mining the severity of hepatic fibrosis could not be avoided.
In summary, the FIB-4 index is validated to noninvasively
predict the severity of hepatic fibrosis, and compared with
APRI it better predicts advanced fibrosis and cirrhosis in
Asian CHC patients. It is noninvasive, simple, and widely
available in clinical practice. Just like eGFR for predicting
renal function, it can help physicians to understand the
severity of hepatic fibrosis and follow up on disease pro-
gression in CHC patients.
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